XML 35 R26.htm IDEA: XBRL DOCUMENT
v3.25.1

Revenues (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Revenue from Contract with Customer [Abstract] |
Schedule of Disaggregation of Revenue by Product and by Geographic Area | Revenues were as follows (in millions):
|  | Three months ended March 31,
|  | 2025 |  | 2024
|  | U.S. |  | ROW |  | Total |  | U.S. |  | ROW |  | Total
Prolia |  | $ | 720 |  |  | $ | 379 |  |  | $ | 1,099 |  |  | $ | 657 |  |  | $ | 342 |  |  | $ | 999 |
Repatha |  | 343 |  |  | 313 |  |  | 656 |  |  | 273 |  |  | 244 |  |  | 517 |
XGEVA |  | 360 |  |  | 206 |  |  | 566 |  |  | 366 |  |  | 195 |  |  | 561 |
ENBREL |  | 504 |  |  | 6 |  |  | 510 |  |  | 561 |  |  | 6 |  |  | 567 |
EVENITY |  | 320 |  |  | 122 |  |  | 442 |  |  | 236 |  |  | 106 |  |  | 342 |
Otezla |  | 343 |  |  | 94 |  |  | 437 |  |  | 293 |  |  | 101 |  |  | 394 |
TEPEZZA |  | 365 |  |  | 16 |  |  | 381 |  |  | 419 |  |  | 5 |  |  | 424 |
BLINCYTO |  | 273 |  |  | 97 |  |  | 370 |  |  | 153 |  |  | 91 |  |  | 244 |
Aranesp |  | 91 |  |  | 249 |  |  | 340 |  |  | 100 |  |  | 249 |  |  | 349 |
KYPROLIS |  | 216 |  |  | 108 |  |  | 324 |  |  | 234 |  |  | 142 |  |  | 376 |
Nplate |  | 201 |  |  | 112 |  |  | 313 |  |  | 190 |  |  | 127 |  |  | 317 |
TEZSPIRE(1) |  | 285 |  |  | — |  |  | 285 |  |  | 173 |  |  | — |  |  | 173 |
Vectibix |  | 135 |  |  | 132 |  |  | 267 |  |  | 120 |  |  | 127 |  |  | 247 |
KRYSTEXXA |  | 236 |  |  | — |  |  | 236 |  |  | 235 |  |  | — |  |  | 235 |
Other products(2) |  | 1,270 |  |  | 377 |  |  | 1,647 |  |  | 963 |  |  | 410 |  |  | 1,373 |
Total product sales(3) |  | $ | 5,662 |  |  | $ | 2,211 |  |  | 7,873 |  |  | $ | 4,973 |  |  | $ | 2,145 |  |  | 7,118 |
Other revenues |  |  |  |  |  | 276 |  |  |  |  |  |  | 329 |
Total revenues |  |  |  |  |  | $ | 8,149 |  |  |  |  |  |  | $ | 7,447 |
_______ (1) TEZSPIRE is marketed by our collaborator AstraZeneca outside the United States. (2) Consists of product sales of our non-principal products. (3) Hedging gains and losses, which are included in product sales, were not material for the three months ended March 31, 2025 and 2024.

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration